Comparative effectiveness and safety of ribavirin plus interferonalpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol

二维码有效期 120s

作者 Zeng Yan-Ming ^[1] Xu Xiao-Lei ^[1] He Xiao-Qing ^[1] Tang Sheng-Quan ^[1] Li Yao ^[1] Huang Yin-Qiu ^[2] Harypursat Vijay ^[1] Chen Yao-Kai ^[3] 学术成果认领

作者单位 Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China ^[1] National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing 400036, China ^[2] Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China; National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing 400036, China ^[3]

主题词利巴韦林(Ribavirin)干扰素α(Interferon-alpha)安全(Safety)病人(Patients)冠状病毒属(Coronavirus)

栏目名称

Correspondence

DOI 10.1097/CM9.0000000000000790

发布时间 2025-04-22

基金项目

This work was supported by the Chongqing Special Research Project for Prevention and Control of Novel Coronavirus Pneumonia（No. cstc2020jscx-fyzx0074）； This work was supported by the Chongqing Special Research Project for Prevention and Control of Novel Coronavirus Pneumonia（No. cstc2020jscx-fyzx0074）